ACS Chemical Biology · 2013 · 60 citations · 39 references
MedicineMolecular MedicinePharmacologyBiochemical PharmacologyClinical PharmacologyMolecular PharmacologyCellular Responses To HypoxiaHemodynamic PharmacologyPulmonary HypertensionSerotonergic PharmacologyAnimal Disease ModelsHypoxia-induced Pulmonary HypertensionPositron Emission Tomography DetectionPositron Emission Tomography FindingsPost-translational ActivationPulmonary Hypertension PharmacologyPulmonary Responses To HypoxiaTranslational Activation
Previous studies in human patients and animal models have suggested that transglutaminase 2 (TG2) is upregulated in pulmonary hypertension (PH), a phenomenon that appears to be associated with the effects of serotonin (5-hydroxytryptamine; 5-HT) in this disease. Using chemical tools to interrogate and inhibit TG2 activity in vivo, we have shown that pulmonary TG2 undergoes marked post-translational activation in a mouse model of hypoxia-induced PH. We have also identified irreversible fluorinated TG2 inhibitors that may find use as non-invasive positron emission tomography probes for diagnosis and management of this debilitating, lifelong disorder. Pharmacological inhibition of TG2 attenuated the elevated right ventricular pressure but had no effect on hypertrophy of the right ventricle of the heart. A longitudinal study of pulmonary TG2 activity in PH patients is warranted.
39
Michael D. Abràmoff, Paulo Magalhães, Sunanda J. Ram · Data Archiving and Networked Services (DANS) · 2004 · 11.9K citations · Full text
Transglutaminase 2 Undergoes a Large Conformational Change upon Activation
Daniel M. Pinkas, Pavel Strop, Axel T. Brünger et al. · PLoS Biology · 2007 · 445 citations · Full text
Life Sciences, Biochemistry, Biology +16